Pharming Group NV Cash Flow Conversion Efficiency
Pharming Group NV cash flow conversion efficiency. Based on the latest financial reports, Pharming Group NV (PHAR) has a cash flow conversion efficiency ratio of 0.006x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.63 Million) by net assets ($268.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pharming Group NV (2005–2025)
Cash flow conversion efficiency of Pharming Group NV from 2005 to 2025. This chart illustrates how Pharming Group NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Pharming Group NV for real-time trading data and today's change.
Pharming Group NV Cash Flow Conversion Ratio Explained
Pharming Group NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pharming Group NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharming Group NV ranked by their cash flow conversion efficiency. Also see how much is Pharming Group NV worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bata India Limited
NSE:BATAINDIA
|
0.166x |
|
Hangzhou Youngsun Intelligent
SHG:603901
|
0.053x |
|
Beijing Topnew Info And Tech Co Ltd
SHE:300895
|
0.032x |
|
Luzerner Kantonalbank AG
LSE:0QNU
|
0.004x |
|
Douglas Dynamics Inc
NYSE:PLOW
|
-0.082x |
|
ASRock Inc
TW:3515
|
-0.040x |
|
IPERIONX LTD SP.ADR/10
F:30Z0
|
N/A |
|
Guangzhou Sanfu New Materials Technology Co. Ltd. A
SHG:688359
|
0.016x |
Annual Cash Flow Conversion Efficiency for Pharming Group NV (2005–2025)
The table below shows the annual cash flow conversion efficiency of Pharming Group NV from 2005 to 2025. Review PHAR cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $277.02 Million | $50.07 Million | 0.181x | +2325.75% |
| 2024-12-31 | $221.06 Million | $-1.79 Million | -0.008x | +89.73% |
| 2023-12-31 | $218.78 Million | $-17.30 Million | -0.079x | -172.06% |
| 2022-12-31 | $204.64 Million | $22.46 Million | 0.110x | -44.05% |
| 2021-12-31 | $192.92 Million | $37.84 Million | 0.196x | -64.78% |
| 2020-12-31 | $150.16 Million | $83.63 Million | 0.557x | -11.83% |
| 2019-12-31 | $117.39 Million | $74.15 Million | 0.632x | -3.39% |
| 2018-12-31 | $70.64 Million | $46.19 Million | 0.654x | -67.83% |
| 2017-12-31 | $22.56 Million | $45.84 Million | 2.032x | +658.01% |
| 2016-12-31 | $28.89 Million | $-10.52 Million | -0.364x | +47.13% |
| 2015-12-31 | $26.06 Million | $-17.95 Million | -0.689x | -289.43% |
| 2014-12-31 | $36.29 Million | $-6.42 Million | -0.177x | +89.31% |
| 2013-12-31 | $6.92 Million | $-11.45 Million | -1.655x | -223.33% |
| 2012-12-31 | $-10.12 Million | $-13.58 Million | 1.342x | -89.84% |
| 2011-12-31 | $-1.54 Million | $-20.34 Million | 13.210x | +2676.91% |
| 2010-12-31 | $13.43 Million | $-6.89 Million | -0.513x | +64.11% |
| 2009-12-31 | $19.07 Million | $-27.24 Million | -1.428x | -75.31% |
| 2008-12-31 | $17.45 Million | $-14.21 Million | -0.815x | -30.04% |
| 2007-12-31 | $50.58 Million | $-31.69 Million | -0.626x | -59.15% |
| 2006-12-31 | $65.78 Million | $-25.89 Million | -0.394x | +12.20% |
| 2005-12-31 | $34.04 Million | $-15.26 Million | -0.448x | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more